Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

Maria Vittoria Dubbinia Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyCorrespondence[email protected]
View further author information

Loredana De Marcob Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Licia Baldic Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Luana Vignoloc Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Fiorella Ilariuccia Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

References

Hutchings M, Radford J, Ansell SM, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol. 2021;39(2):185–195.
PubMed Web of Science ®Google Scholar
Parente P, Graziano P, Scalzulli P, et al. Brentuximab-related apoptotic colopathy. Pathology. 2020;52(4):483–484.
PubMed Web of Science ®Google Scholar
Karamchandani DM, Chetty R. Apoptotic colopathy: a pragmatic approach to diagnosis. J Clin Pathol. 2018;71(12):1033–1040.
PubMed Web of Science ®Google Scholar
Tang L, Wang J, Lin N, et al. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol. 2021;12:800879.
PubMed Web of Science ®Google Scholar
Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020;115(2):202–210.
PubMed Web of Science ®Google Scholar
Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities. Version 1.2019. J Natl Compr Cancer Netw. 2019;17(3):255–289.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date